5334-39-4, name is 3-Methyl-4-nitro-1H-pyrazole, belongs to pyrazoles-derivatives compound, is considered to be a conventional heterocyclic compound, which is widely used in drug synthesis. The chemical synthesis route is as follows. Recommanded Product: 5334-39-4
To a solution of 3-methyl-4-nitro-lH-pyrazole (1 -1, 398 nig, 3.13 mmol) in DMF (10 niL) was added NaH (125 mg, 3.13 mmol, 60% purity) at 0 C, then the reaction was stirred at 20 C for 1 h. Then, (3-methyl- 5,6,7,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyridin-6-yl) methanesulfonate (604 mg, 2.61 mmol, 70% purity) in DMF (4 mL) was added to the solution at 20 C. Then, the mixture was stirred at 80 C for 12 h. The reaction solution was added with NH4Q solution (20 ml,), extracted with DCM:MeOH (20 mL chi 3, ratio=3: l). The organic layers were combined, dried over Na2S04, filtered and concentrated under reduced pressure. The crude product was purified by prep-TLC (DCM:MeOH = 5: 1) to give a mixture of 3-niethy3~6~(3-methyi-4~nitro^ and 3- methyl-6-(5~methyl-4-nitro-pyra^ as a yellow gum. LCMS: RT 0.925 min, m/z = 263.1 | M – H j ‘ . NMR (400 MHz, CDC13): delta 8.25 (s, 0.6 H), 8.13 (s, 0.3 H), 4.68 – 4.81 (m, 1 H), 4.14 – 4.42 (m, 2 H), 3.02 – 3.31 (m, 2 H), 2.77 (s, 1 H), 2.55 (s, 2 H), 2.44 – 2.53 (m, 4 H), 2.43 (s, 1 1H 1).To a mixture of 3-methyl-6-(3-methyl-4-nitro-pyrazol-l-yl)-5,6,7,8-tetrahydro-[l,2,4]triazolo[4,3-aJpyri and 3-me1hyl-6-(5-methyl-4-nitro-pyrazol-l-yl)-5,6,7,8-tetrahydro-[l ,2,4]triazolo[4,3-a]pyridm (100 mg, 381.29 muetaiotaomicron) in Me OH (10 mL) was added Pd/C (10%, 50 mg) under N2. The suspension was degassed and purged with H2 for 3 times. The mixture was stirred under H2 ( 15 psi) at 20 C for 5 h. The reaction solution was filtered through a pad of celite, the filtrate was concentrated under reduced pressure to give a crude 5 -methyl- 1 -(3 -methyl-5 ,6,7,8 -tetrahydro- j 1 ,2,4 jtriazolo [4,3 -a]pyridin-6-yl)pyrazol-4-amine and 3 – m.ethyi~-(3-ni6thyl~5,6,7,8~tetrahy LCMS: RT0.173 min, m/z = 233.1 [M+H]+.
The synthetic route of 5334-39-4 has been constantly updated, and we look forward to future research findings.